Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: A review of 59 consecutive cases treated at a single institute

Oncology Research

Volumn 17, Issue 3, 2008, Pages 137-149

  Akutsu, Miyuki ^a   Tsunoda, Saburo ^a   Izumi, Tohru ^a   Tanaka, Masaru ^a   Katano, Susumu ^a   Inoue, Koichi ^a   Igarashi, Seiji ^a   Hirabayashi, Kaoru ^a   Furukawa, Yusuke ^b   Ohmine, Ken ^a,b   Sato, Kazuya ^a,b   Kobayashi, Hiroyuki ^a,b   Ozawa, Keiya ^b   Kirito, Keita ^a,c   Nagashima, Takahiro ^a,c   Teramukai, Satoshi ^d   Fukushima, Masanori ^d   Kano, Yasuhiko ^a  

^a TOCHIGI CANCER CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Aggressive lymphoma; CNS lymphoma; G CSF; TCC NHL 91

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; INTERSTITIAL PNEUMONIA; ISCHEMIC HEART DISEASE; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 47549096234     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504008785055549     Document Type: Article

References (44)

1. Armitage, J. O. Treatment of non-Hodgkin's lymphoma. N. Engl. J. Med. 328:1023-1030; 1993.
2. Fisher, R. I.; Gaynor, E. R.; Dahlberg, S.; Oken, M. M.; Grogan, T. M.; Mize, E. M.; Glick, J. H.; Coltman, Jr., C. A.; Miller, T. P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 328:1002-1006; 1993.
3. Skarin, A. T.; Canellos, G. P.; Rosenthal, D. S.; Case, Jr., D. C.; MacIntyre, J. M.; Pinkus, G. S.; Moloney, W. C.; Frei, 3rd, E. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose MTX alternating with standard agents (M-BACOD). J. Clin. Oncol. 1:91-98; 1983.
4. Klimo, P.; Connors, J. M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann. Int. Med. 102:596-602; 1985.
5. Coleman, M.; Armitage, J. O.; Gaynor, M.; McDermott, D.; Weisenburger, D. D.; Adler, K.; Beshevkin, M.; Silver, R. T.; Reisman, A. M.; Pasmantier, M. W. The COP-BLAM programs; evolving chemotherapy concepts in large cell lymphoma. Semin. Hematol. 25(2 Suppl. 2): 23-33; 1988.
6. Longo, D. L.; DeVita, Jr., V. T.; Duffey, P. L.; Wesley, M. N.; Ihde, D. C.; Hubbard, S. M.; Gilliom, M.; Jaffe, E. S.; Cossman, J.; Fisher, R. I.; Young, R. C. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma, results of a pros-pective randomized trial. J. Clin. Oncol. 9: 25-38; 1991.
7. Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P.; Reyes, F.; Lederlin, P.; Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-242; 2002.
8. Mounier, N.; Briere, J.; Gisselbrecht, C.; Emile, J. F.; Lederlin, P.; Sebban, C.; Berger, F.; Bosly, A.; Morel, P.; Tilly, H.; Bouabdallah, R.; Reyes, F.; Gaulard, P.; Coiffier, B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284; 2003.
9. Sehn, L. H.; Berry, B.; Chhanabhai, M.; Fitzgerald, C.; Gill, K.; Hoskins, P.; Klasa, R.; Savage, K. J.; Shenkier, T.; Sutherland, J.; Gascoyne, R. D.; Connors, J. M. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861; 2007.
10. Nademanee, A.; Forman, S. J. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large B-cell lymphoma. Semin. Hematol. 43:240-250; 2006.
11. Norton, L.; Simon, R. The Norton-Simon hypothesis revisited. Cancer Treat. Rep. 70:163-169; 1986.
12. Goldie, J. H.; Coldman, A. J. The genetic origin of drug-resistance in neoplasms, Implication for systemic therapy. Cancer Res. 44:3643-3653; 1984.
13. Coiffier, B.; Gisselbrecht, C.; Herbrecht, R.; Tilly, H.; Bosly, A.; Brousse, N. LNH-84 regimen, a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J. Clin. Oncol. 7:1018-1026; 1989.
14. Yazawa, Y.; Takagi, T.; Asakura, S.; Suzuki, K.; Kano, Y. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agentson human cancer cell lines. J. Orthop. Sci. 4:231-237; 1999.
15. Kano, Y.; Suzuki, K.; Akutsu, M.; Suda, K. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 6:440-445; 1992.
16. Kano, Y.; Ohnuma, T.; Okano, T.; Holland, J. F. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res. 48:351-356; 1988.
17. Kano, Y.; Akutsu, M.; Suzuki, K.; Yoshida, M. Effects of carboplatin in combination with other anticancer agents on huma leukemia cell lines. Leuk. Res. 17:113-119; 1993.
18. Akutsu, M.; Furukawa, Y.; Tsunoda, S.; Izumi, T.; Ohmine, K.; Kano, Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia 16:1808-1817; 2002.
19. Evans, W. E.; Crom, W. R.; Abromowitch, M.; Dodg, R.; Look, A. T.; Bowman, W. P.; George, S. L.; Pui, C. H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N. Engl. J. Med. 314: 471-477; 1986.
20. Levitt, L. J.; Dawson, D. M.; Rosenthal, D. S.; Moloney, W. C. CNS involvement in the non-Hodgkin's lymphomas. Cancer 45:545-552; 1980.
21. Wolf, M. M.; Olver, I. N.; Ding, J. C.; Cooper, I. A.; Liew, K. H.; Madigan, J. P. Non-Hodgkin's lymphoma involving the central nervous system. Aust. NZ J. Med. 15:16-21; 1985.
22. Perez-Soler, R.; Smith, T. L.; Cabanillas, F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer 57:971-977; 1986.
23. Bollen, E. L.; Brouwer, R. E.; Hamers, S.; Hermans, J.; Kluin, M.; Sankatsing, S. U.; A-Tjak, R. V.; Charvat, M. V.; Kluin-Nelemans, J. C. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch. Neurol. 54:854-859; 1997.
24. van Besien, K.; Ha, C. S.; Murphy, S.; McLaughlin, P.; Rodriguez, A.; Amin, K.; Forman, A.; Romaguera, J.; Hagemeister, F.; Younes, A.; Bachier, C.; Sarris, A.; Sobocinski, K. S.; Cox, J. D.; Cabanillas, F. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178-1184; 1998.
25. Haioun, C.; Besson, C.; Lepage, E.; Thieblemont, C.; Simon, D.; Rose, C.; Tilly, H.; Sonet, A.; Lederlin, P.; Attal, M.; Briere, J.; Reyes, F. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis; a GELA study on 974 patients. Groupe d'tudes des Lymphomes de l'Adulte. Ann. Oncol. 11:685-690; 2000.
26. Tomita, N.; Kodama, F.; Kanamori, H.; Motomura, S.; Ishigatsubo, Y. Secondary central nervous system lymphoma. Int. J. Hematol. 84:128-135; 2006.
27. Cheson, B. D.; Horning, S. J.; Coiffier, B.; Shipp, M. A.; Fisher, R. I.; Connors, J. M.; Lister, T. A.; Vose, J.; Grillo-Lopez, A.; Hagenbeek, A.; Cabanillas, F.; Klippensten, D.; Hiddemann, W.; Castellino, R.; Harris, N. L.; Armitage, J. O.; Carter, W.; Hoppe, R.; Canellos, G. P. Report of an international workshop to standardize response criteria for non-Hodgkin&'s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 17:1244-1253; 1999.
28. Cheson, B. D.; Pfistner, B.; Juweid, M. E.; Gascoyne, R. D.; Specht, L.; Horning, S. J.; Coiffier, B.; Fisher, R. I.; Hagenbeek, A.; Zucca, E.; Rosen, S. T.; Stroobants, S.; Lister, T. A.; Hoppe, R. T.; Dreyling, M.; Tobinai, K.; Vose, J. M.; Connors, J. M.; Federico, M.; Diehl, V. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J. Clin. Oncol. 25:579-586; 2007.
29. Shipp, M. A. Predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 329: 987-994; 1993.
30. Yahalow, J. Principles, indications, and techniques of radiation therapy of lymphomas. In: Canellos, G. P.; Lister, T. A.; Young, B. D., eds. The Lymphomas, 2nd ed. Philadelphia: Saunders Elsevier; 2006:203-224.
31. Shipp, M. A.; Harrington, D. P.; Klatt, M. M.; Jochelson, M. S.; Pinkus, G. S.; Marshall, J. L.; Rosenthal, D. S.; Skarin, A. T.; Canellos, G. P. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann. Int. Med. 104:757-765; 1986.
32. Wilder, R. B.; Rodriguez, M. A.; Ha, C. S.; Pro, B.; Hess, M. A.; Cabanillas, F.; Cox, J. D. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91:2440-2446; 2001.
33. Ferreri, A. J.; Dell'Oro, S.; Reni, M.; Ceresoli, G. L.; Cozzarini, C.; Ponzoni, M.; Villa, E. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B-cell lymphomas. Oncology 58:219-226; 2000.
34. Aviles, A.; Fernandezb, R.; Perez, F.; Nambo, M. J.; Neri, N.; Talavera, A.; Castaneda, C.; Gonzalez, M.; Cleto, S. Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome. Leuk. Lymphoma 45:1385-1389; 2004.
35. Jagannath, S.; Velasquez, W. S.; Tucker, S. L.; Fuller, L. M.; McLaughlin, P. W.; Manning, J. T.; North, L. B.; Cabanillas, F. C. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J. Clin. Oncol. 4:859-865; 1986.
36. Cheung, C. W.; Burton, C.; Smith, P.; Linch, D. C.; Hoskin, P. J.; Ardeshna, K. M. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: Current practice in the UK. Br. J. Haematol. 131:193-200; 2005.
37. Chua, S. L.; Seymour, J. F.; Streater, J.; Wolf, M. M.; Januszewicz, E. H.; Prince, H. M. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk. Lymphoma 43:1783-1788; 2002.
38. Arriagada, R.; Le Chevalier, T.; Borie, F.; Riviere, A.; Chomy, P.; Monnet, I.; Tardivon, A.; Viader, F.; Tarayre, M.; Benhamou, S. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J. Natl. Cancer Inst. 87:183-190; 1995.
39. Le Pechoux, C.; Arriagada, R. Prophylactic cranial irradiation in small cell lung cancer. Hematol. Oncol. Clin. North Am. 18:355-372; 2004.
40. Gordon, L. I.; Young, M.; Weller, E.; Habermann, T. M.; Winter, J. N.; Glick, J.; Ghosh, C.; Flynn, P.; Cassileth, P. A. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas, analysis of response; toxicity; and dose intensity. Blood 94:3307-3314; 1999.
41. Gisselbrecht, C.; Lepage, E.; Molina, T.; Quesnel, B.; Fillet, G.; Lederlin, P.; Coiffier, B.; Tilly, H.; Gabarre, J.; Guilmin, F.; Hermine, O.; Reyes, F. Groupe d'Etude des Lymphomes de l'Adulte. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J. Clin. Oncol. 20:2472-2479; 2002.
42. Wilson, W. H.; Grossbard, M. L.; Pittaluga, S.; Cole, D.; Pearson, D.; Drbohlav, N.; Steinberg, S. M.; Little, R. F.; Janik, J.; Gutierrez, M.; Raffeld, M.; Staudt, L.; Cheson, B. D.; Longo, D. L.; Harris, N.; Jaffe, E. S.; Chabner, B. A.; Wittes, R.; Balis, F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas, a pharmacodynamic approach with high efficacy. Blood 99:2685-2693; 2002.
43. Blayney, D. W.; LeBlanc, M. L.; Grogan, T.; Gaynor, E. R.; Chapman, R. A.; Spiridonidis, C. H.; Taylor, S. A.; Bearman, S. I.; Miller, T. P.; Fisher, R. I.; Southwest Oncology Group. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate-and high-grade lymphoma; a phase II study of the Southwest Oncology Group (SWOG9349). J. Clin. Oncol. 21:2466-2473; 2003.
44. Dunleavy, K.; Davis, R. E.; Landgren, O.; Staudt, L. M.; Wilson, W. H. BCL-6 and rituximab in diffuse large B-cell lymphoma: Where are we? Blood 109:843-844; 2007.